{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T20:19:19Z","timestamp":1648930759734},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40264-021-01096-6","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T09:02:37Z","timestamp":1627549357000},"page":"1011-1013","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Authors\u2019 Reply to Braillon and Martin\u2019s Comment on \u201cProposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)\u201d"],"prefix":"10.1007","volume":"44","author":[{"given":"Priya","family":"Bahri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Inoubli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Dogn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine M. J. M.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"1096_CR1","doi-asserted-by":"publisher","unstructured":"Braillon A, Martin M. Comment on \u201cProposals for engaging patients and healthcare professionals in risk minimisation from an analysis of stakeholder input to the EU valproate assessment using the novel Analysing Stakeholder Safety Engagement Tool (ASSET)\u201d. Drug Saf. 2021. https:\/\/doi.org\/10.1007\/s40264-021-01101-y\u00a0","DOI":"10.1007\/s40264-021-01101-y"},{"key":"1096_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40264-020-01005-3","volume":"44","author":"P Bahri","year":"2021","unstructured":"Bahri P, Morales DR, Inoubli A, Dogn\u00e9 J-M, Straus SMJM. Proposals for engaging patients and healthcare professionals in risk minimisation from an analysis of stakeholder input to the EU valproate assessment using the novel Analysing Stakeholder Safety Engagement Tool (ASSET). Drug Saf. 2021;44:193\u2013209. https:\/\/doi.org\/10.1007\/s40264-020-01005-3.","journal-title":"Drug Saf"},{"key":"1096_CR3","unstructured":"European Medicines Agency. Pharmacovigilance Risk Assessment Committee. https:\/\/www.ema.europa.eu\/en\/committees\/pharmacovigilance-risk-assessment-committee-prac. Accessed 31 May 2021."},{"key":"1096_CR4","unstructured":"Pharmacovigilance Risk Assessment Committee. PRAC strategy on measuring the impact of pharmacovigilance activities. Rev 1. London: European Medicines Agency; 2017. https:\/\/www.ema.europa.eu\/en\/documents\/other\/prac-strategy-measuring-impact-pharmacovigilance-activities_en.pdf. Accessed 3 June 2020."},{"key":"1096_CR5","unstructured":"European Medicines Agency (EMA). Patients\u2019 and Consumers\u2019 Working Party. https:\/\/www.ema.europa.eu\/en\/committees\/working-parties-other-groups\/chmp\/patients-consumers-working-party. Accessed 31 May 2021."},{"key":"1096_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40264-019-00874-7","volume":"43","author":"CE Hoeve","year":"2020","unstructured":"Hoeve CE, Francisca RDC, Zomerdijk I, Sturkenboom MCJM, Straus SMJM. Description of the risk management of medication errors for centrally authorised products in the European Union. Drug Saf. 2020;43:45\u201355.","journal-title":"Drug Saf"},{"key":"1096_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40264-020-00993-6","volume":"44","author":"RDC Francisca","year":"2021","unstructured":"Francisca RDC, Baba E, Hoeve CE, Zomerdijk IM, Sturkenboom MCJM, Straus SMJM. Introduction or discontinuation of additional risk minimisation measures during the life cycle of medicines in Europe. Drug Saf. 2021;44:63\u201372.","journal-title":"Drug Saf"},{"key":"1096_CR8","unstructured":"European Medicines Agency. Good pharmacovigilance practices: Module XVI\u2013risk minimisation measures: selection of tools and effectiveness indicators (Rev 3); Module XVI Addendum II\u2014methods for effectiveness evaluation. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/good-pharmacovigilance-practices. Accessed 31 May 2021."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01096-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01096-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01096-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T15:27:47Z","timestamp":1629214067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01096-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1096"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01096-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]},"assertion":[{"value":"4 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The views expressed in this response are the authors\u2019 personal views and may not be understood or quoted as being made on behalf of or reflect the position of the EMA or one of its committees or working parties.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No specific funding was received for the conduct of this response.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Priya Bahri, Daniel R. Morales, Adrien Inoubli, Jean-Michel Dogn\u00e9 and Sabine M.J.M. Straus have no conflicts of interests that are directly relevant to the content of this response.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study [CitationRef removed] used the records described and referenced with the access option as applicable in Sect. 2 Methods and the data analyses are provided in Appendix 3 online.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors participated in preparing this response and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}